Skip to main content

Table 2 Geometric mean plasma levels3 of E2, FSH, P4 and SHBG according to use of HRT among postmenopausal women

From: Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysis

E2 dosage category   E2 ¤ nmol/L FSH IU/L P4 nmol/L SHBG nmol/L
  n 95% CI 95% CI 95% CI 95% CI
No HRT 2651 0.07 (0.06–0.07) 69.6 (65.9–73.5) 0,82 (0.76–0.89) 42.4 (40.2–44.8)
HRT      
   HRT without E2 20 0.07 (0.06–0.08) 53.4 (44.0–64.9) 0,65 (0.49–0.87) 34.9 (28.7–42.4)
   Vaginal E2 5 0.07 (0.05–0.10) 70.4 (47.8–104) 0,99 (0.56–1.76) 33.4 (22.6–49.4)
   Patches 9 0.15 (0.12–0.19) 36.4 (27.3–48.5) 1,05 (0.68–1.61) 47.0 (35.1–62.8)
   Oral 1 mg 232 0.23 (0.20–0.27) 36.9 (30.6–44.6) 0,46 (0.35–0.60) 52.1 (43.4–62.5)
   Oral 2 mg 9 0.29 (0.22–0.38) 18.7 (14.1–25.0) 0,79 (0.51–1.21) 62.5 (46.8–83.6)
ANCOVA3   p < 0.01 p < 0.01 p < 0.01 p < 0.01
  1. 1FSH: n = 252
  2. 2 FSH: n = 21
  3. 3 Covariates included in addition to age: BMI, BMI and alcohol, ¤ BMI and BMI*age interaction term. Parity did not contribute significantly to the model for any of the analyses, and was omitted.